Connect with us

Press Releases

Hemophiliac Launches Biotechnology Company to Develop a Cure for Hemophilia

Fixx Pharmaceuticals was founded by Jesse John Francis Clark – a man dedicated to improving the lives of those suffering from bleeding disorders.

Avatar

Published

on


​Fixx Pharmaceuticals Inc. is pleased to announce the upcoming launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California.

Fixx Pharmaceuticals Inc. is a new biotechnology company launching on September 1, 2020. The company is focused on developing therapies specifically targeted to treat patients suffering from bleeding disorders with the use of CRISPR gene editing.

One of Fixx’s main areas of focus is Hemophilia. Hemophilia is an inherited bleeding disorder in which the blood does not clot properly. Currently, there are 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally.

“Hemophilia was discovered in 1803 – it’s almost 2021 and we still don’t have a cure,” says founder of Fixx Pharmaceuticals, Jesse John Francis Clark. “I was born with severe hemophilia and I’m determined to develop a cure. There are many challenges for people with hemophilia, the most common of which are joint bleeds and deformity, which affect the quality of life for many of us. When we do develop a cure, we will help patients in developing countries first. For example, India has a high patient load of over 18,000 and less than 20% have insurance.”

Jesse John Francis Clark is an internationally known professional, entrepreneur, and passionate advocate for people living with Hemophilia and related bleeding disorders. Born with severe Hemophilia, Clark founded HemoAware Corporation in 2018, a non-profit organization dedicated to enriching the lives of people with inherited bleeding disorders through advocacy, education, and technology.

For more information about Fixx Pharmaceuticals Inc., please visit http://www.fixxpharma.com.

About the Company​

Fixx Pharmaceuticals’ mission is to develop targeted therapies to support patients suffering from bleeding disorders, specifically Hemophilia. The company was founded in 2020 and is located in Las Vegas and California.

Jesse John Francis Clark
Fixx Pharmaceuticals Inc.
+1 888-321-3499
email us here

Source: https://www.newswire.com/news/hemophiliac-launches-biotechnology-company-to-develop-a-cure-for-21200023

Continue Reading

Press Releases

Emmy-Winning Pili Montilla’s New Project – ‘Fun for Life Radio’ on DASH – Prescribes Effective Remedy for Coronavirus Pandemic Blues

Avatar

Published

on

Press Release updated: Nov 23, 2020 07:53 EST


​Fun For Life Radio is the newest station on Dash Radio, streaming an eclectic mix of captivating talk and discover-worthy tunes. “The station was created by Fun For Life Entertainment Group to not only enable the company’s constellation of artists and influencers to more fully connect with their audiences, but also to provide comfort and intellectual enrichment to stressed-out homebound listeners,” shares FFLR’s Emmy award-winning TV Host & producer Pili Montilla, who also hosts Truth and Tunes with Pili Montilla on the station. The timing couldn’t be better, as media consumption has risen due to the stress of the coronavirus pandemic, and working from home means more time for people to engage with entertainment and particularly radio according to Nielsen Music. There has also been a significant boost in radio listening due to a surge in smart speaker usage. 

“We’ve created a winning formula with our blend of thought-provoking talk and great music, curated by warm personalities so listeners can lean back, learn and hopefully relax, all without commercials,” says Montilla. Other current shows include Relationship Renegades with actress Rachele Brooke Smith and health expert Emilio Palafox, Hollywood Uncensored with film critic/podcaster Dana Buckler, and The Saint James Band Hour with George Castrinos and Jake Marcus Wand. “Whether you want to work on your love life, get to really know your favorite artists or just listen to an awesome mix of new and classic tunes – we’ve got you covered!” Montilla adds.           

Listen to FFLR on the DASH Radio app for free 24/7.

About Pili Montilla:

Emmy-winning TV host & producer Pili Montilla is the go-to host in the bilingual entertainment world. She created/ hosted the Emmy-winning music show Té Para Tres con Pili Montilla and serves as a multi-network host for the Latin Billboards red carpet, Latin Grammys events, New York Magazine’s Vulture Festival and many more. Pili’s latest projects include Pili, Raúl & La Música a bilingual Latin music podcast alongside renowned DJ Raúl Campos (KCRW) and her new Fun For Life Radio show Truth & Tunes with Pili Montilla where she interviews top cultural influencers who share their favorite songs. www.pilimontilla.com.

About Dash Radio:
Dash is the global leader in curated, lean-back audio experiences. Since 2015, Dash has become the world’s largest all-original digital broadcaster, empowering many of the world’s most prominent artists, influencers and brands to take radio directly to fans without fees or subscriptions. Featuring over 80 curator-championed original stations, Dash is available on 50+ platforms – inside nearly every connected car service, smart home product, and iOS device. With no traditional commercials, Dash Radio offers the perfect music discovery experience free of charge, while offering brands a more authentic and effective way to engage these audiences worldwide. For more information: http://www.dashradio.com.

Press Contact: PR@funforliferadio.com

Source: Fun For Life Entertainment Group

Source: https://www.newswire.com/news/emmy-winning-pili-montillas-new-project-fun-for-life-radio-on-dash-21262306

Continue Reading

Press Releases

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate) for…

Avatar

Published

on

SOUTH SAN FRANCISCO, Calif. and PETACH TIKVA, Israel, Nov. 23, 2020 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.

“This approval of TAVALISSE provides ITP patients and physicians in Canada with a new oral treatment option, the only therapy to address the underlying platelet destruction that causes ITP,” said Raul Rodriguez, Rigel’s president and CEO. “With Medison as our collaborative partner, we believe TAVALISSE is well positioned for commercial success in the Canadian market.”

In October 2019, Rigel entered into exclusive license agreements with Medison to commercialize TAVALISSE in Canada and Israel. With the approval from Health Canada, Medison intends to launch TAVALISSE in Canada in Q1 2021. In Israel, a decision on the new drug application (NDA) is anticipated during Q2 2021.  

“Our multiregional partnership with Rigel to deliver TAVALISSE in Canada and Israel is a testament to our ongoing efforts to extend the reach of highly innovative therapies to patients across international markets,” said Meir Jakobsohn, founder and CEO of Medison Pharma.

“Given our specialization in delivering cutting-edge therapeutics, TAVALISSE is a natural fit for Medison’s expertise and will enable us to bring a much-needed treatment option to Canadian ITP patients,” said Joe O’Neill, GM of Medison Canada.  

Fostamatinib is commercially available in the U.S. under the brand name TAVALISSE® (fostamatinib disodium hexahydrate) tablets, which is the first and only spleen tyrosine kinase (SYK) inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to a previous treatment.

About ITP
In patients with ITP (immune thrombocytopenia), the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP include fatigue, excessive bruising and bleeding. People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death. In addition to fostamatinib, current therapies for ITP include steroids, blood platelet production boosters (TPO-RAs) and splenectomy. However, not all patients respond to existing therapies. As a result, there remains a significant medical need for additional treatment options for patients with ITP.

About Medison Pharma
Medison is one of the world’s largest commercial partners of leading global biotech companies. Medison is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in international markets, focusing on Canada, Israel, and Central Eastern Europe. Medison runs a corporate venture arm with a dedicated research and evaluation team boasting deep scientific and commercial backgrounds. Medison also operates a scouting program to cater its partners and is an active investor in life science projects around drug development and digital health. For more information, visit www.medison.co.il and follow Medison on LinkedIn.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel’s pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and is marketed in Europe under the name TAVLESSE® (fostamatinib).

Fostamatinib1 is currently being studied in a Phase 3 trial for the treatment of warm autoimmune hemolytic anemia (AIHA); an NIH/NHLBI-Sponsored Phase 2 trial for the treatment of hospitalized COVID-19 patients, in collaboration with Inova Health System; and a Phase 2 trial for the treatment of COVID-19 being conducted by Imperial College London. Additionally, Rigel plans to launch a Phase 3 clinical trial of fostamatinib for the treatment of hospitalized COVID-19 patients in the fourth quarter of 2020.

Rigel’s other clinical programs include an ongoing Phase 1 study of R8351, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program, and an ongoing Phase 1 study of R5521, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

Please see www.TAVALISSE.com for the full Prescribing Information.

1The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Forward Looking Statements
This release contains forward-looking statements relating to, among other things, the potential future commercial success of TAVALISSE in the Canadian market, Rigel’s ability to receive further payments under the Medison agreement, the timing of a launch of TAVALISSE in Canada, the timing for a decision on the NDA in Israel, and the expansion of the global opportunity for TAVALISSE through more marketing authorizations and launches. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “plans,” “may,” “anticipates,” “believe,” “expects” and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based on Rigel’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the commercialization and marketing of fostamatinib in the U.S. and Europe; risks that the FDA, European Medicines Agency (EMA) or other regulatory authorities may make adverse decisions regarding fostamatinib or any of Rigel’s product candidates; risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials; the availability of resources to develop and, if approved, commercialize fostamatinib or any other of Rigel’s product candidates; the progress of our and our collaborators’ product development programs, including clinical testing, and the timing of results thereof; our expectations with respect to regulatory submissions and approvals; our research and development expenses; protection of our intellectual property; market competition; as well as other risks detailed from time to time in Rigel’s reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. In addition, the ongoing COVID-19 pandemic may result in further delays in Rigel’s studies and trials, or impact Rigel’s sales and ability to obtain supply of fostamatinib. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Medison Contact
Maya Nix
Corporate Communications Lead
Phone: +972.3.925.0260
Email: [email protected]

Rigel IR Contact: David Burke
Phone: 650.624.1232
Email: [email protected]

SOURCE Rigel Pharmaceuticals, Inc.; Medison Pharma

Related Links

http://www.rigel.com

Source: https://www.prnewswire.com:443/news-releases/rigel-and-medison-announce-health-canada-approval-of-tavalisse-an-oral-medication-for-the-treatment-of-adults-with-chronic-immune-thrombocytopenia-301178615.html

Continue Reading

Press Releases

Growing Uptake of Grilled Food to Boost the Electric Grills Market Growth to 2028

DUBLIN, Nov. 23, 2020 /PRNewswire/ — The “Electric Grills Market By Product Type, By Application – Growth, Future Prospects & Competitive Analysis, 2020 – 2028” report has been added to ResearchAndMarkets.com’s offering. The electric grills market worldwide is expected to grow with a…

Avatar

Published

on

DUBLIN, Nov. 23, 2020 /PRNewswire/ — The “Electric Grills Market By Product Type, By Application – Growth, Future Prospects & Competitive Analysis, 2020 – 2028” report has been added to ResearchAndMarkets.com’s offering.

The electric grills market worldwide is expected to grow with a CAGR of 7.1% during the forecast period from 2020 to 2028, starting from US$ 555.3Mn in 2019. An inclination towards healthy grilled food, changing lifestyles, and preference for homemade grilled food are the major growth drivers for the electric grills market. Rapid technological advancement is also gaining traction as now Bluetooth and Wi-Fi enabled electric grills are there in the market. In addition, the ongoing COVID-19 crisis has resulted in lockdown restrictions and people have been spending more time at home. Thereby, there has been a rising trend in home cooking since a lot of people have been avoiding visiting local restaurants and diners. As a result of these factors, high growth is expected in the electric grills market during the forecast period.

Electric Smokers to Continue as the Market Leader

The electric smokers segment holds the highest market share in the electric grills industry with more than 60% of the market revenue, as of 2019. With the growing penetration of electric grills in restaurants and hotels, the electric smokers segment is the leader. Electric smokers are available in a smaller form or a refrigerator style to cook plenty of food at the same time. Nowadays, people are more concerned about their health and grilled food is often considered healthy, which in turn increasing the demand for electric smokers worldwide.

Asia Pacific to Emerge as the Market Leader

In 2019, by revenue, North America was the leader in the electric grills market followed by Europe with more than 30% of market share.  Asia Pacific will be the fastest-growing region due to inclination towards healthy food and an increase in per capita income. Rising preference for homemade grilled food in countries such as Japan, China, and India are the major growth factors in the region.

Major players are focusing on strategies such as innovation-led product launch to increase their market presence. For instance, in 2017, Koninklijke Philips N.V. launched a smoke-less indoor grill with up to 80% less smoke and with advanced infrared technology. Brand enhancement and mergers & acquisitions are expected to remain a key strategy in years to come. Some of the prominent players operating in the electric grills market include The Weber-Stephen Products LLC, Middleby Corporation, Taylor Company Inc., Roller Grill International SA, Dimplex North America Limited, DeLonghi SpA, Coleman Company, Inc., Midea Group, Char-Broil Llc, Zojirushi, Koninklijke Philips N.V. and others.

This research report presents the analysis of each segment from 2018 to 2028 considering 2019 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each respective segment calculated for the forecast period from 2020 to 2028.

Key questions answered in this report

  • What was the market size of electric grills in 2018 and 2019 along with forecast up to 2028?
  • Which is the largest regional market by revenue for electric grills?
  • What are the major trends followed in overall electric grills across different regions?
  • What are the key market trends and high-growth opportunities observed in the electric grills market?
  • What are the drivers of the electric grills market?
  • Who are the key electric grills companies leading the market?
  • What are the key strategies adopted by the leading electric grills companies in the market?

Key Topics Covered:

1. Preface

2. Executive Summary
2.1. Market Snapshot: Global Electric Grills Market
2.2. Global Electric Grills Market, by Product Type, 2019 (US$ Bn)
2.3. Global Electric Grills Market, by Application, 2019 (US$ Bn)
2.4. Global Electric Grills Market, by Geography, 2019 (US$ Bn)

3. Market Dynamics
3.1. Introduction
3.2. Market Dynamics
3.3. Attractive Investment Proposition, by Geography, 2019
3.4. Market Positioning of Key Players, 2019

4. Global Electric Grills (EG) Market, by Product Type,2018-2028 (US$ Bn)

5. Global Electric Grills (EG) Market, by Application, 2018-2028 (US$ Bn)

6. North America Electric Grills (EG) Market Analysis, 2018-2028 (US$ Bn)

7. Europe Electric Grills (EG) Market Analysis, 2018-2028 (US$ Bn)

8. Asia Pacific Electric Grills (EG) Market Analysis, 2018-2028 (US$ Bn)

9. Rest of the World Electric Grills (EG) Market Analysis, 2018-2028 (US$ Bn)

10. Company Profiles
10.1. The Weber-Stephen Products LLC
10.2. Middleby Corporation
10.3. Taylor Company Inc.
10.4. Roller Grill International SA
10.5. Dimplex North America Limited
10.6. DeLonghiSpA
10.7. Coleman Company, Inc.
10.8. Midea Group
10.9. Char-Broil Llc
10.10. Zojirushi
10.11. Koninklijke Philips N.V.

For more information about this report visit https://www.researchandmarkets.com/r/cxo9ez

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Source: https://www.prnewswire.com:443/news-releases/growing-uptake-of-grilled-food-to-boost-the-electric-grills-market-growth-to-2028-301178790.html

Continue Reading
Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Blockchain3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Saas3 hours ago

Press Releases3 hours ago

Emmy-Winning Pili Montilla’s New Project – ‘Fun for Life Radio’ on DASH – Prescribes Effective Remedy for Coronavirus Pandemic Blues

Blockchain3 hours ago

Swipe (SXP) Waiting to Make Decisive Move After Breaking Past Resistance

Blockchain3 hours ago

Join the Utopia Ecosystem and Change Your Future – with Crypton

Blockchain3 hours ago

4 ok, amiért a Bitcoin újra csúcsra ért

Blockchain3 hours ago

Binance Coin, Ontology, DigiByte Price Analysis: 23 November

Press Releases3 hours ago

Treasury Metals Announces Commencement of 10,000m Drilling Program at Goldlund Gold Project

Press Releases3 hours ago

Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics

Press Releases3 hours ago

Great Panther Announces Updated Mineral Resource Estimates at GMC; Measured and Indicated Resources Increase by 17% and Inferred Resources More than Double

Press Releases3 hours ago

Growing Uptake of Grilled Food to Boost the Electric Grills Market Growth to 2028

Press Releases3 hours ago

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

Venture Capital3 hours ago

Impeding Freedom?

Private Equity4 hours ago

GI Partners buys Valet Living from Harvest Partners, Ares Management private equity arm

Private Equity4 hours ago

Bain Capital raises $800m for second impact investing fund

Private Equity4 hours ago

Blackstone said to eye at least $5bn for second Asia private equity fundraise

Blockchain4 hours ago

Nem lesz többé titkoscoin? Lenyomozható lesz a monero is

Private Equity4 hours ago

Japanese bank SMBC takes $30m stake in UK fintech firm OakNorth

Blockchain4 hours ago

Bitcoin Faces Volatility Rise as Futures Market Shows Signs of Overheating

Startup4 hours ago

Future looking bleak for Amazon as CCI decides fate of buyout

Blockchain4 hours ago

China’s CCB withdraws $3B blockchain bond to be listed on Malaysian exchange

Blockchain4 hours ago

Bitcoin-Verknappung: PayPal und Square kaufen neues BTC-Angebot leer

Trending